This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Nov. 25, 2013 /PRNewswire/ -- The Female Health Company (Nasdaq-CM: FHCO) today announced that it will be presenting at the
Sixth Annual LD MICRO "Main Event" Micro-Cap Conference on
Thursday, December 5, 2013. The conference will be held at the Luxe Sunset Bel Air Hotel, which is located at 11461 Sunset Boulevard in
Los Angeles, California.
The presentation by
O. B. Parrish, Chief Executive Officer, and
Michele Greco, Chief Financial Officer, is scheduled for
10:00 a.m. Pacific Standard Time on
Thursday, December 5, 2013. Management will be available during the day for one-on-one meetings. To schedule a meeting, please contact your LD MICRO representative or
Eric Lahiji at
About LD MICRO
LD MICRO is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published an annual list of recommended stocks, as well as comprehensive reports on select companies throughout the year. The firm also hosts the LD MICRO Micro-Cap Growth Conference for investors in December of each year. This year's conference will feature presentations by over 225 publicly-traded companies and is expected to attract more than 1,000 attendees.
About The Female Health Company
The Female Health Company, based in
Chicago, Illinois, manufactures and markets
the FC2 Female Condom® (FC2), which is available in the U.S. and approximately 143 other countries globally. The Company owns certain worldwide rights to the
FC2 Female Condom®, including patents that have been issued in a number of countries around the world. The patents cover the key aspects of FC2, including its overall design and manufacturing process. The
FC2 Female Condom® is the only currently available female-controlled product approved by the FDA that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared
FC2 for purchase by U.N. agencies.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:The statements in this release which are not historical facts are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated
For more information about the Female Health Company visit the Company's website at
http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to
SOURCE The Female Health Company